The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-07. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Serous acinar cells are roughly pyramid shape, with the apex of the pyramid pointing towards to the center of the (roughly spherical) acinus. Inside of the cell on the side with the apex, there are specialize saliva-material containing structures called secretory granules. Compared to mucous acinar cells, their nuclei is more round, and centrally located.
== Mechanism == Pyridoxine is in the vitamin B family of vitamins. It is required by the body to make amino acids, carbohydrates, and lipids. Sources in the diet include fruit, vegetables, and grain. It is also required for muscle phosphorylase activity associated with glycogen metabolism.
=== Genes of lactoferrin === At least 60 gene sequences of lactoferrin have been characterized in 11 species of mammals. In most species, stop codon is TAA, and TGA in Mus musculus. Deletions, insertions and mutations of stop codons affect the coding part and its length varies between 2,055 and 2,190 nucleotide pairs. Gene polymorphism between species is much more diverse than the intraspecific polymorphism of lactoferrin. There are differences in amino acid sequences: 8 in Homo sapiens, 6 in Mus musculus, 6 in Capra hircus, 10 in Bos taurus and 20 in Sus scrofa. This variation may indicate functional differences between different types of lactoferrin. In humans, lactoferrin gene LTF is located on the third chromosome in the locus 3q21-q23. In oxen, the coding sequence consists of 17 exons and has a length of about 34,500 nucleotide pairs. Exons of the lactoferrin gene in oxen have a similar size to the exons of other genes of the transferrin family, whereas the sizes of introns differ within the family. Similarity in the size of exons and their distribution in the domains of the protein molecule indicates that the evolutionary development of lactoferrin gene occurred by duplication. Study of polymorphism of genes that encode lactoferrin helps selecting livestock breeds that are resistant to mastitis.
Sources: en.wikipedia.org
== History == Thyroxine was first isolated in pure form in 1914 at the Mayo Clinic by Edward Calvin Kendall from extracts of hog thyroid glands. The hormone was synthesized in 1927 by British chemists Charles Robert Harington and George Barger.
He announced that youth become "slaves" to cannabis, "continuing addiction until they deteriorate mentally, become insane, turn to violent crime and murder." He promoted a racialized view of drug use, saying that blacks and Latinos were the primary abusers. In Congressional testimony, he declared "of all the offenses committed against the laws of this country, the narcotic addict is the most frequent offender." He was also an effective administrator and diplomat, attending international drug conferences and steadily expanding the FBN's influence. In 1935, the New York Times reported on President Roosevelt's public support of the Uniform State Narcotic Drug Act under the headline, "Roosevelt Asks Narcotic War Aid". The Uniform Law Commission developed the act to address the 1914 Harrison Act's lack of state-level enforcement provisions, creating a model law reflecting the Harrison Act that states could adopt to replace the existing patchwork of state laws. Anslinger and the FBN were centrally involved in drafting the act, and in convincing states to adopt it.
== Other natriuretic peptides == Humans have three natriuretic peptide (NPPx) genes: NPPA for ANP, NPPB for BNP, and NPPC for CNP. All of these have similar structures and effects. In particular, brain natriuretic peptide (BNP) – a misnomer; it is secreted by ventricular myocytes – is similar to ANP in its effect. It acts via atrial natriuretic peptide receptors but with 10-fold lower affinity than ANP. The biological half-life of BNP, however, is twice as long as that of ANP, and that of NT-proBNP is even longer, making these peptides better choices than ANP for diagnostic blood testing. Alternative cleavages of NPPA produces four peptides with alleged natriuretic properties: long-acting natriuretic peptide (LANP, 26–55), vessel dilator (56–92), kaliuretic peptide (104–123), and urodilatin (120–151). The former two are of a dubious nature. Adrenomedullin, produced by a gene not of the NPPx family, also has a natriuretic property. It works through a different receptor and is generally not considered an NPP. In addition to the mammalian natriuretic peptides (ANP, BNP, CNP), other natriuretic peptides with similar structure and properties have been isolated elsewhere in the animal kingdom. A salmon natriuretic peptide known as salmon cardiac peptide has been described, and dendroaspis natriuretic peptide (DNP) has been found in the venom of the green mamba, as well as an NP in a species of African snake.
Sources: en.wikipedia.org
== History == In 1863, German chemists Ferdinand Reich and Hieronymus Theodor Richter were testing ores from the mines around Freiberg, Saxony. They dissolved the minerals pyrite, arsenopyrite, galena and sphalerite in hydrochloric acid and distilled raw zinc chloride. Reich, who was color-blind, employed Richter as an assistant for detecting the colored spectral lines. Knowing that ores from that region sometimes contain thallium, they searched for the green thallium emission spectrum lines. Instead, they found a bright blue line. Because that blue line did not match any known element, they hypothesized a new element was present in the minerals. They named the element indium, from the indigo color seen in its spectrum, after the Latin indicum, meaning 'of India'. Richter went on to isolate the metal in 1864. An ingot of 0.5 kg (1.1 lb) was presented at the World Fair 1867. Reich and Richter later fell out when Richter claimed to be the sole discoverer.
== Ethics == AI has potential benefits and potential risks. AI may be able to advance science and find solutions for serious problems: Demis Hassabis of DeepMind hopes to "solve intelligence, and then use that to solve everything else". However, as the use of AI has become widespread, several unintended consequences and risks have been identified. In-production systems can sometimes not factor ethics and bias into their AI training processes, especially when the AI algorithms are inherently unexplainable in deep learning.
Evidence from the study of nuclear and mitochondrial genomes Paleolithic dog remains, indicative of presence and wide distribution of a genetically homogeneous dog population across Europe and Anatolia by at least 14,300 years ago, is presented by Marsh et al. (2026). Bergström et al. (2026) reconstruct the evolutionary history of early European dogs on the basis of the study of ancient DNA from Paleolithic and Mesolithic remains, reporting evidence of genetic diversification of European dogs before 14,200 years ago, and evidence of contribution of Mesolithic dogs to the ancestry of later, Neolithic European dogs. Kropczyk & Marciszak (2026) study the composition of the canid assemblage from caves from Mount Połom (Poland), including Pleistocene wolves that are morphologically comparable with extant wolves and only slightly smaller, representing one of the oldest large-bodied wolves in Europe reported to date. Purported partial dentary of a member of the genus Plionarctos from the Miocene Rattlesnake Formation (Oregon, United States) is considered to be only identifiable as belonging to an indeterminate bear by Schubert & Samuels (2026), who consider Plionarctos edensis from the latest Hemphillian Mt. Eden Local Fauna from California to be oldest known confirmed short-faced bear. Ruiz-Ramoni et al. (2026) identify fossil material of a specimen of Arctotherium wingei from Taima-Taima (Venezuela), find A. wingei to be the only species of Arctotherium present in the region, and review the fossil record of bears in Venezuela. Lopatin et al.
Macrophages are professional phagocytes and are highly specialized in removal of dying or dead cells and cellular debris. This role is important in chronic inflammation, as the early stages of inflammation are dominated by neutrophils, which expend themselves and are ingested by macrophages. Macrophages normally present themselves at the wound site within 2 days following the injury. The neutrophils are at first attracted to a site, where they perform their function and die, before they or their neutrophil extracellular traps are phagocytized by the macrophages. The first wave of neutrophils acts for approximately 2 days at the site and signals to attract macrophages. These macrophages will then ingest the aged neutrophils. The removal of dying cells is, to a greater extent, handled by fixed macrophages, which will stay at strategic locations such as the lungs, liver, neural tissue, bone, spleen and connective tissue, ingesting foreign materials such as pathogens and recruiting additional macrophages if needed. The phagocytosis and clearance of apoptotic remains is called efferocytosis and is also carried out by other cell types, not all of which are professional phagocytes. When a macrophage ingests a pathogen, the pathogen becomes trapped in a phagosome, which then fuses with a lysosome. Within the phagolysosome, enzymes and toxic peroxides digest the pathogen. However, some bacteria (such as Mycobacterium tuberculosis) have become resistant to these methods of digestion.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.